CohortId TreatmentId VisitId cohortId.label visitId.sequenceNumMin 2047 101 16500 Group 1A: HIV-uninfected participants 0.0000 2046 102 16500 Group 1A Placebo: HIV-uninfected participants 0.0000 2049 103 16500 Group 1B: HIV-uninfected participants 0.0000 2048 102 16500 Group 1B Placebo: HIV-uninfected participants 0.0000 2051 104 16500 Group 1C: HIV-uninfected participants 0.0000 2050 102 16500 Group 1C Placebo: HIV-uninfected participants 0.0000 2053 101 16500 Group 2A: HIV-infected on ART (<50 cp/ml) 0.0000 2052 102 16500 Group 2A Placebo: HIV-infected on ART (<50 cp/ml) 0.0000 2055 103 16500 Group 2B: HIV-infected on ART (<50 cp/ml) 0.0000 2054 102 16500 Group 2B Placebo: HIV-infected on ART (<50 cp/ml) 0.0000 2057 104 16500 Group 2C: HIV-infected on ART (<50 cp/ml) 0.0000 2056 102 16500 Group 2C Placebo: HIV-infected on ART (<50 cp/ml) 0.0000 2058 104 16500 Group 3A: HIV-Infected off ART (VL 2x10^3 – 1x10^5 cp/ml) 0.0000 2059 103 16500 Group 3B: HIV-Infected off ART (VL 2x10^3 – 1x10^5 cp/ml) 0.0000 2060 101 16500 Group 3C: HIV-Infected off ART (VL 2x10^3 – 1x10^5 cp/ml) 0.0000 2061 104 16500 Group 3D: HIV-Infected off ART (VL 1x10^2 – 2x10^3 cp/ml) 0.0000 2062 103 16500 Group 3E: HIV-Infected off ART (VL 1x10^2 – 2x10^3 cp/ml) 0.0000 2063 101 16500 Group 3F: HIV-Infected off ART (VL 1x10^2 – 2x10^3 cp/ml) 0.0000